Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study
By:
References
- 1. Kunecki M, Oleksy T, Biernat J, Kukla P, Szwajkos K, Podolec P, Deja M, Gołba K, Płazak W. Ischemic conditioning of human heart muscle depends on opioid-receptor system. Folia Med Cracov. 2017;57(2):31-39.10.20418/jrcd.vol2no6.228
- 2. Li PC, Yang YC, Hwang GY, Kao LS, Lin CY. Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9(2):e85909.10.1371/journal.pone.0085909391190024498266
- 3. Sorsa T, Polleselo P, Solaro RJ. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitizer with cardiac troponin c. Moll Cell Biochem. 2004;266:87-107.10.1023/B:MCBI.0000049141.37823.1915646030
- 4. Haikala H, Polleselo P. Calcium sensitivity enhancers. IDrugs. 2000;3:1199-205.
- 5. Kaheinen P, Polleselo P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37:367-74.10.1097/00005344-200104000-0000311300649
- 6. Erdei N, Papp Z, Polleselo P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol. 2006;148:696-702.10.1038/sj.bjp.0706781175187216715115
- 7. Pollesello P, Papp Z. The cardioprotective effect of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50:257-63.10.1097/FJC.0b013e318098623017878752
- 8. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Ilida H, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68:522-31.10.1067/mcp.2000.11097211103755
- 9. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Verkkala K, et al. Effect of new calcium sensitizer levosimendan on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery by-pass grafting. Eur Heart J. 1998;19:660-8.10.1053/euhj.1997.08069597417
- 10. Toller W, Algottson L, Guarracino F, Hormann C, Knotzer J, Lehman A, et al. Perioperative use of levosimendan: best practice in operative settings. J Cardiothorac Vasc Anesth. 2013;27:361-6.10.1053/j.jvca.2012.04.00722658687
- 11. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol. 1994;74:2448.10.1111/j.1600-0773.1994.tb01106.x8090694
- 12. Maytin M, Colucci WS. Cardioprotection: A new paradigm in the management of acute heart failure syndromes. Am J Cardiol. 2005;96:26G-31G.10.1016/j.amjcard.2005.07.01816181820
- 13. Li PC, Yang YC, Hwang GY, Kao LS, Lin CY Inhibition of reverse-mode sodium-calcium exchanger activity and apoptosis by levosimendan in human cardiomyocyte progenitor cell-derived cardiomyocytes after anoxia and reoxygenation. PLoS One. 2014;9(2):e85909. 14. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68(5):807-12.10.1016/j.bcp.2004.05.01815294443
- 14. Kopustinskiene DM, Pollesello P, Saris NE. Potassium-specific effects of levosimendan on heart mitochondria. Biochem Pharmacol. 2004;68(5):807-12.10.1016/j.bcp.2004.05.018
- 15. Kunecki M, Płazak W, Roleder T, Biernat J, Oleksy T, Podolec P, Gołba KS. Opioidergic postconditioning’ of heart muscle during ischemia/reperfusion injury. Cardiol J. 2017;24(4):419-26.10.5603/CJ.a2016.009027734456
- 16. Toller W, Heringlake M, Guarracino F, Algotson L, Alvarez J, Argyriadau H, et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol. 2015;184:323-36.10.1016/j.ijcard.2015.02.02225734940
- 17. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A. A role for the RISK pathway and KATP channels in pre- and post-conditioning induced by levosimendan in the isolated guinea-pig heart. Br J Pharmacol. 2008;154:41-50.10.1038/bjp.2008.52243898718297097
- 18. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43:2177-82.10.1016/j.jacc.2004.02.05215193677
- 19. Levijoki J, Pollesello P, Kaheinen P, Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol. 2001;419:243-8.10.1016/S0014-2999(01)00997-911426847
- 20. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol. 2012;17:125-30.
- 21. Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome. Rev Esp Cardiol. 2008;61:471-9.10.1157/13119990
- 22. Adegboyega PA, Haque AK, Boor PJ. Extensive myocytolysis as a marker of sudden cardiac death. Cardiovasc Pathol. 1996;5(6):315-21.10.1016/S1054-8807(96)00041-525851788
Language: English
Page range: 219 - 223
Submitted on: Aug 30, 2022
Accepted on: Dec 11, 2022
Published on: Feb 9, 2023
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2023 Marcin Kunecki, Tomasz Oleksy, Jerzy Nozynski, Piotr Podolec, Jolanta Biernat, Marek Andrzej Deja, Krzysztof Stanislaw Golba, Wojciech Plazak, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.